New Tools to Define Intervention in Asymptomatic Carotid Disease

This meta-analysis included 14 studies and compared the uptake of fluorodeoxyglucose (18F-FDG) according to positron emission tomography (PET)/computed tomography (CT) in symptomatic versus asymptomatic patients, demonstrating a significantly higher uptake in patients with symptomatic lesions. While PET/CT imaging of atheroma is a tool under investigation, with limited applicability in clinical practice, in a relatively close future, it might give insight into plaque biology so as to identify cases most likely to result in stroke. If so, it would become another tool to define intervention in patients who are asymptomatic but present highly inflamed and eventually unstable plaque.

This work included 539 symptomatic and asymptomatic patients who were assessed through PET/CT. Results were clear: patients with symptomatic lesions demonstrated a significantly higher tracer uptake (mean difference: 0.94; p < 0.0001).

 

Approximately 80% of strokes are ischemic in nature, and carotid lesions are deemed the source in 10% of cases. There is strong evidence that early intervention is key in reducing stroke rates in patients with significant symptomatic ipsilateral carotid disease. However, in asymptomatic patients, there are very few tools supporting intervention and most are in clear support of conservative management by best medical therapy available. Only a small proportion of asymptomatic patients with significant carotid artery lesions will develop a stroke or transient ischemic attack; having tools that will help to identify these patients might lead to interventions that will reduce the risk of future events. The use of 18F-FDG in PET/CT might be this new tool.

 

Conclusion

The use of 18F-FDG in PET/CT can demonstrate carotid plaque inflammation as a marker of symptomatic disease. Further studies are required to add these imaging techniques to clinical practice.

 

Original title: 18F-FDG Uptake on PET/CT in Symptomatic Versus Asymptomatic Carotid Disease: A Meta-Analysis.

Reference: Mohammed M. Chowdhury et al. Eur J Vasc Endovasc Surg (2018). Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...